Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.63 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | SNCA | P37840 | 2/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213630 | 0.91 | NSD2 (0.55) | NSD2CTBP2POLBMEN1KMT2A | |
| SCHEMBL5317577 | 0.87 | NSD2 (0.61) | NSD2CTBP2CA12CA9SIGMAR1 | |
| SCHEMBL5317572 | 0.86 | NSD2 (0.60) | NSD2CTBP2CA12CA9SIGMAR1 | |
| SCHEMBL19049393 | 0.84 | NSD2 (0.58) | NSD2CA12CA9SIGMAR1TMEM97 | |
| SCHEMBL14540450 | 0.83 | NSD2 (0.57) | NSD2CA12CA9SIGMAR1TMEM97 | |
| SCHEMBL5117737 | 0.82 | NSD2 (0.50) | NSD2CTBP2SIGMAR1TMEM97POLB | |
| SCHEMBL10194674 | 0.82 | NSD2 (0.56) | NSD2CA12CA9SIGMAR1TMEM97 | |
| SCHEMBL19002498 | 0.82 | NSD2 (0.56) | NSD2SIGMAR1TMEM97POLBNPC1 | |
| SCHEMBL12505597 | 0.82 | MEP1A (0.56) | NSD2CA12CA9NPC1MEN1 | |
| SCHEMBL7401773 | 0.81 | HTT (0.51) | NSD2CTBP2SIGMAR1TMEM97POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. | 2022-09-15 | — | — | US | disclosed |
| EP-4017545-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | Biogen MA Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021034924-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | BIOGEN MA INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| CN-104302358-B | The assimilation compound of isoquinolin 1 and their therapeutical uses of 3 aryl 5 substitution | 癌症研究协会:皇家癌症医院 | 2017-12-05 | — | — | CN | disclosed |
| CN-104302358-A | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | CANCER RES INST ROYAL | 2015-01-21 | — | — | CN | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | NSD2 57/4885CTBP2 1021/4885CA12 4465/4885 |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | NSD2 2965/4885CTBP2 4621/4885CA12 4556/4885 |
| US-20220290140-A1 | TRANS-CYCLOOCTENE LABELED ANTISENSE OLIGONUCLEOTIDES, RADIO LABELED TETRAZINE AND METHODS | TK1, TTR, TALDO1 | NSD2 4648/4885CTBP2 506/4885CA12 596/4885 |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | NSD2 2221/4885CTBP2 3551/4885CA12 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.